Today: 21 May 2026
Micron stock slips today as China’s CXMT targets $4.2 billion DRAM IPO
31 December 2025
2 mins read

Micron stock slips today as China’s CXMT targets $4.2 billion DRAM IPO

NEW YORK, December 31, 2025, 12:00 ET — Regular session

  • Micron Technology shares fell about 1.8% in late-morning trading, underperforming a slightly softer U.S. market.
  • A Reuters report on China’s CXMT IPO plans put fresh focus on future DRAM supply and competition.
  • A recent Form 4 showed Micron’s CFO transferred shares into an estate-planning trust.

Micron Technology, Inc. shares were down about 1.8% at $287.35 in late-morning New York trading on Wednesday. The stock has ranged from $284.45 to $293.91 so far in the session, with about 9.2 million shares traded.

The move matters now because Micron has become a high-sensitivity bet on memory pricing, where profits can swing quickly when supply or demand shifts. After a sharp run this year, investors have shown less tolerance for headlines that hint at fresh capacity.

Micron has been among the strongest S&P 500 performers in 2025, with storage-linked names such as Western Digital and Seagate also posting outsized gains as AI-linked infrastructure demand lifted data storage and memory themes.

One new focus on Wednesday was China’s ChangXin Memory Technologies (CXMT), which said in an IPO prospectus it aims to raise 29.5 billion yuan ($4.22 billion) in Shanghai to upgrade DRAM production lines and develop advanced memory. DRAM, or dynamic random access memory, is widely used in PCs and servers; CXMT is also investing in high-bandwidth memory (HBM), a faster type of DRAM used with AI processors, with production at a new HBM packaging facility expected to start by late 2026, Reuters reported.

Separately, Taiwan’s Ministry of Economic Affairs has granted Micron’s Taiwan unit a NT$4.7 billion ($149.5 million) subsidy under an innovation and R&D program aimed at developing high-performance and high-bandwidth memory chips, the Taipei Times reported. The ministry said the project would run through October 2028.

Micron also traded in step with a modestly risk-off tape into the year-end, with Wall Street’s main indexes slightly lower in thin holiday dealing. “Describing 2025 as ‘resilient’ might be an understatement,” said Adam Turnquist, chief technical strategist at LPL Financial, in a Reuters market note. Reuters

Chip stocks were broadly softer, with the PHLX Semiconductor index down 0.38% on the day.

On the filings front, Micron’s chief financial officer Mark Murphy disclosed transferring 35,000 shares on Dec. 24 to a grantor retained annuity trust, a common estate-planning structure, according to a Form 4 filed on Dec. 29.

Micron’s board has also declared a quarterly dividend of $0.115 per share, payable on Jan. 14, 2026, to shareholders of record as of the close of business on Dec. 29, the company said in its latest quarterly results release.

U.S. equity markets are open regular hours on New Year’s Eve, but will be closed on Jan. 1 for the New Year’s Day holiday and reopen on Jan. 2, according to a market-hours notice published on Wednesday.

For Micron, investors are watching whether tight memory supply conditions hold into early 2026 and how quickly rivals add DRAM capacity without undermining pricing. Demand for HBM — the premium memory used in AI servers — remains a key swing factor for expectations around margins and earnings power.

The CXMT listing plan adds another variable. Even small shifts in projected supply can move memory stocks because the industry is cyclical and pricing can turn faster than factories can be adjusted.

With year-end liquidity thinning, Micron’s next directional cue is likely to come from fresh signals on data-center spending, contract pricing discussions across memory, and any additional disclosures around competitors’ expansion timelines.

Stock Market Today

  • Nifty 50 and Sensex Expected to Open Higher on May 21 Amid US-Iran Ceasefire Hopes
    May 20, 2026, 10:38 PM EDT. Indian stock indices Sensex and Nifty 50 are poised for a positive start on May 21, following global market gains and optimism over a US-Iran ceasefire deal. The Sensex gained 117.54 points to close at 75,318.39 and Nifty 50 rose 41 points to 23,659 on May 20. Technical analysts highlight a sideways trading range with key Sensex support at 74,500 and resistance near 76,000. Nifty 50 shows bullish candlestick patterns, suggesting buying strength near lower levels and a breakout above 23,800 could trigger further gains. Derivatives data show call and put writing aligning with these support and resistance zones, indicating cautious but optimistic market sentiment.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking
Previous Story

Premium Bonds January 2026 draw date is set — here’s when NS&I results drop and why savers are rethinking

XRP price today: Ripple-linked token slips as year-end trading thins — key levels before 2026
Next Story

XRP price today: Ripple-linked token slips as year-end trading thins — key levels before 2026

Go toTop